Cargando…

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising research direction. Poly (ADP-ribose) polymerase (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Heng, Wei, Miaoyan, Xu, Jin, Hua, Jie, Liang, Chen, Meng, Qingcai, Zhang, Yiyin, Liu, Jiang, Zhang, Bo, Yu, Xianjun, Shi, Si
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053129/ https://www.ncbi.nlm.nih.gov/pubmed/32122376 http://dx.doi.org/10.1186/s12943-020-01167-9

Ejemplares similares

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
por: Zhang, Yiyin, et al.
Publicado: (2019)

A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance
por: Meng, Qingcai, et al.
Publicado: (2020)

The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction
por: Tan, Zhen, et al.
Publicado: (2020)

From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors
por: Wei, Miaoyan, et al.
Publicado: (2021)

Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance
por: Zhang, Yiyin, et al.
Publicado: (2019)

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2020)

GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation
por: Meng, Qingcai, et al.
Publicado: (2018)

Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer
por: Lu, Siyuan, et al.
Publicado: (2022)

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Yiyin, et al.
Publicado: (2019)

Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer
por: Lu, Siyuan, et al.
Publicado: (2022)

Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer
por: Dong, Jia, et al.
Publicado: (2023)

Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)
por: Li, Jialin, et al.
Publicado: (2023)

Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer
por: Liang, Chen, et al.
Publicado: (2023)

Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
por: Hua, Jie, et al.
Publicado: (2018)

The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
por: Tang, Rong, et al.
Publicado: (2020)

Emerging roles of the solute carrier family in pancreatic cancer
por: Wu, Zijian, et al.
Publicado: (2021)

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
por: Liu, Xiaomeng, et al.
Publicado: (2019)

Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis
por: Fang, Zengli, et al.
Publicado: (2020)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
por: Tang, Rong, et al.
Publicado: (2023)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1)
por: Wei, Miaoyan, et al.
Publicado: (2019)

Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment
por: Rong, Zeyin, et al.
Publicado: (2021)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDAC
por: Dong, Mingwei, et al.
Publicado: (2023)

Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features
por: Lei, Yalan, et al.
Publicado: (2021)

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis
por: Rong, Zeyin, et al.
Publicado: (2021)

Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis
por: Fang, Zengli, et al.
Publicado: (2023)

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner
por: Tan, Zhen, et al.
Publicado: (2022)

Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis
por: Meng, Qingcai, et al.
Publicado: (2017)

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017)

Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT
por: Meng, Qingcai, et al.
Publicado: (2023)

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
por: Tang, Rong, et al.
Publicado: (2020)

A Novel Validated Recurrence Stratification System Based on (18)F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer
por: Wei, Miaoyan, et al.
Publicado: (2021)

Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine
por: Nilov, Dmitry, et al.
Publicado: (2020)

Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
por: Piombino, Claudia, et al.
Publicado: (2022)

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
por: Wu, Yongsong, et al.
Publicado: (2023)

The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives
por: Fang, Zengli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oio73uadac6choeuqm49uoobq1